Corcept Therapeutics Inc. (NASDAQ:CORT) Director Patrick G. Enright sold 36,941 shares of the firm’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $9.34, for a total value of $345,028.94. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Corcept Therapeutics Inc. (NASDAQ:CORT) opened at 9.18 on Friday. Corcept Therapeutics Inc. has a 12 month low of $3.22 and a 12 month high of $10.00. The company has a market cap of $1.02 billion, a PE ratio of 235.38 and a beta of 1.64. The stock’s 50 day moving average is $7.78 and its 200 day moving average is $6.22.

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

COPYRIGHT VIOLATION WARNING: “Insider Selling: Corcept Therapeutics Inc. (CORT) Director Sells $345,028.94 in Stock” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and reposted in violation of United States & international copyright & trademark laws. The correct version of this report can be viewed at https://www.thecerbatgem.com/2016/11/26/insider-selling-corcept-therapeutics-inc-cort-director-sells-345028-94-in-stock.html.

Several large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can acquired a new stake in Corcept Therapeutics during the second quarter valued at about $100,000. Smith Asset Management Group LP raised its stake in Corcept Therapeutics by 69.2% in the second quarter. Smith Asset Management Group LP now owns 30,080 shares of the company’s stock valued at $164,000 after buying an additional 12,300 shares during the last quarter. Falcon Point Capital LLC raised its stake in Corcept Therapeutics by 12.3% in the second quarter. Falcon Point Capital LLC now owns 96,575 shares of the company’s stock valued at $527,000 after buying an additional 10,569 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Corcept Therapeutics by 18.4% in the second quarter. Bank of New York Mellon Corp now owns 320,872 shares of the company’s stock valued at $1,752,000 after buying an additional 49,807 shares during the last quarter. Finally, California State Teachers Retirement System raised its stake in Corcept Therapeutics by 19.5% in the second quarter. California State Teachers Retirement System now owns 156,638 shares of the company’s stock valued at $855,000 after buying an additional 25,574 shares during the last quarter. 41.24% of the stock is owned by institutional investors and hedge funds.

CORT has been the subject of several recent analyst reports. FBR & Co restated a “buy” rating on shares of Corcept Therapeutics in a research note on Thursday, August 4th. Zacks Investment Research downgraded Corcept Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 4th. Finally, Piper Jaffray Cos. set a $12.00 target price on Corcept Therapeutics and gave the company a “buy” rating in a research note on Wednesday, October 19th.

About Corcept Therapeutics

Corcept Therapeutics Inc is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company’s focus is on those disorders that are associated with a steroid hormone cortisol. Elevated levels and abnormal release patterns of cortisol have been implicated in a range of human disorders.

5 Day Chart for NASDAQ:CORT

Receive News & Stock Ratings for Corcept Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Inc. and related stocks with our FREE daily email newsletter.